Sanofi To Move Two NMEs Into Phase III In 2004, For Total Of Nine
Executive Summary
Sanofi-Synthelabo plans to move two new molecular entities into Phase III during 2004
You may also be interested in...
Medicare Obesity Policy Change Will Help Acomplia Launch, Sanofi Says
Medicare's recent announcement about obesity coverage policies sends a positive signal for the upcoming launch of Sanofi-Synthelabo's Acomplia, the company said during a July 21 conference call
Medicare Obesity Policy Change Will Help Acomplia Launch, Sanofi Says
Medicare's recent announcement about obesity coverage policies sends a positive signal for the upcoming launch of Sanofi-Synthelabo's Acomplia, the company said during a July 21 conference call
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call